Health-related quality of life in patients with cutaneous rosacea: a systematic review.

Health-related quality of life (HRQoL) of rosacea patients is a relevant outcome measure in research and clinical practice. A review of the literature was systematically carried out regarding levels of HRQoL of patients with rosacea, including associations between HRQoL scores, demographic and clinical characteristics. Searches were performed in Cochrane, PubMed, EMBASE, PsycINFO, CINAHL and LILACS. HRQoL studies in patients with cutaneous rosacea, using validated HRQoL instruments, published between 1991 and 2014, were included. Data extraction was performed independently by 2 authors. Study design, demographics, clinical characteristics and HRQoL scores were summarized per HRQoL questionnaire. Associations between HRQoL, demographic and clinical characteristics were explored. Out of 984 references, 12 studies were included. Three HRQoL instruments were used: Short Form-36 (SF-36), Dermatology Life Questionnaire Index (DLQI) and Rosacea Quality of Life Index (RosaQoL). Because of the heterogeneity of the included studies, data synthesis was hardly feasible. All studies reported a negative impact on HRQoL, which appeared to be associated with disease severity and age. Results regarding the association with sex and subtype were mixed. With regard to the clinical relevance of HRQoL scores of rosacea patients, it seems that rosacea has a small to moderate effect on HRQoL.

[1]  Z. Fedorowicz,et al.  Interventions for rosacea. , 2015, Cochrane Database of Systematic Reviews.

[2]  G. Schmid‐Ott,et al.  Symptom severity and psychological sequelae in rosacea: Results of a survey , 2014, Psychology, health & medicine.

[3]  J. Ortonne,et al.  An observational cross‐sectional survey of rosacea: clinical associations and progression between subtypes , 2013, The British journal of dermatology.

[4]  A. Abdullah,et al.  The effect of pulsed dye laser on the dermatology life quality index in erythematotelangiectatic rosacea patients: an assessment. , 2013, The Journal of clinical and aesthetic dermatology.

[5]  C. Prinsen,et al.  Interpretation of Skindex-29 scores: response to Sampogna and Abeni. , 2012, The Journal of investigative dermatology.

[6]  L. Delong,et al.  Overview of health status quality-of-life measures. , 2012, Dermatologic clinics.

[7]  C. Gessert,et al.  Randomized, double‐blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea , 2012, International journal of dermatology.

[8]  M. Sprangers,et al.  Health-related quality-of-life assessment in dermatologic practice: relevance and application. , 2012, Dermatologia clinica.

[9]  M. Augustin,et al.  Quality of Health Care of Rosacea in Germany from the Patient’s Perspective: Results of the National Health Care Study RosaReal 2009 , 2011, Dermatology.

[10]  B. Elewski,et al.  Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  H. Baldwin.  A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. , 2010, Cutis.

[12]  D. Egemen,et al.  The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities , 2010, The British journal of dermatology.

[13]  Suephy C. Chen,et al.  A pilot study in discrepancies in quality of life among three cutaneous types of rosacea. , 2010, Journal of the American Academy of Dermatology.

[14]  M. Sprangers,et al.  Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors. , 2010, The Journal of investigative dermatology.

[15]  H. Korting,et al.  Current topical and systemic approaches to treatment of rosacea , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  A. Moreira,et al.  Quality of life and rosacea: Pulsed dye laser impact , 2009, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[17]  A. Finlay,et al.  The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results , 2008, The British journal of dermatology.

[18]  I. Schaefer,et al.  Prevalence of Skin Diseases in a Cohort of 48,665 Employees in Germany , 2008, Dermatology.

[19]  Jan Busschbach,et al.  Critical review of generic and dermatology-specific health-related quality of life instruments. , 2007, The Journal of investigative dermatology.

[20]  O. Chassany,et al.  Poor Reporting of Quality of Life Outcomes in Dermatology Randomized Controlled Clinical Trials , 2007, Dermatology.

[21]  M. Chren,et al.  A pilot quality-of-life instrument for acne rosacea. , 2007, Journal of the American Academy of Dermatology.

[22]  P. Tharyan,et al.  Randomized Controlled Clinical Trials - Critical Issues , 2007 .

[23]  J. Ring,et al.  Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle‐controlled double‐blind trial , 2007, The British journal of dermatology.

[24]  B. Elewski,et al.  Azelaic acid gel 15%: clinical versatility in the treatment of rosacea. , 2006, Cutis.

[25]  F. Sampogna,et al.  Measuring quality of life of patients with different clinical types of psoriasis using the SF‐36 , 2006, The British journal of dermatology.

[26]  A. Finlay,et al.  Translating the science of quality of life into practice: What do dermatology life quality index scores mean? , 2005, The Journal of investigative dermatology.

[27]  A. Fleischer,et al.  The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. , 2005, Journal of drugs in dermatology : JDD.

[28]  K. Landow.  Rosacea The battle goes on , 2005, Comprehensive therapy.

[29]  F. Powell.  Clinical practice. Rosacea. , 2005, The New England journal of medicine.

[30]  W. James,et al.  Rosacea: I. Etiology, pathogenesis, and subtype classification. , 2004, Journal of the American Academy of Dermatology.

[31]  M. Liang,et al.  Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. , 2004, Journal of the American Academy of Dermatology.

[32]  M. Goldman,et al.  Rosacea: where are we now? , 2004, Journal of drugs in dermatology : JDD.

[33]  A. Finlay,et al.  10 years experience of the Dermatology Life Quality Index (DLQI). , 2004, The journal of investigative dermatology. Symposium proceedings.

[34]  A. Kligman.  A Personal Critique on the State of Knowledge of Rosacea , 2004, Dermatology.

[35]  R. Shikiar,et al.  Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials , 2003, Health and Quality of Life Outcomes.

[36]  M. Sprangers,et al.  The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. , 2002, Archives of dermatology.

[37]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[38]  B. Rzany,et al.  Lebensqualität bei Patienten mit Rosacea und Rhinophym , 2001 .

[39]  J. Wright,et al.  A comparison of different indices of responsiveness. , 1997, Journal of clinical epidemiology.

[40]  A Y Finlay,et al.  Quality of life measurement in dermatology: a practical guide , 1997, The British journal of dermatology.

[41]  S J Zyzanski,et al.  Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. , 1996, The Journal of investigative dermatology.

[42]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[43]  R. Epstein,et al.  Interpretation of quality of life changes , 1993, Quality of Life Research.

[44]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[45]  J. Murphy,et al.  Patient-Reported Outcomes , 2018, Quality Spine Care.

[46]  A. Wozniacka,et al.  [Quality of life in patients with rosacea]. , 2008, Przeglad lekarski.

[47]  H. Waldorf,et al.  Rosacea: clinical presentation and pathophysiology. , 2006, Journal of drugs in dermatology : JDD.

[48]  M. Berg,et al.  An epidemiological study of rosacea. , 1989, Acta dermato-venereologica.